Can hCG Cause Gynecomastia?
Yes, human chorionic gonadotropin (hCG) can cause gynecomastia in men through its stimulation of testicular testosterone production and subsequent aromatization to estradiol, creating an elevated estrogen-to-androgen ratio.
Mechanism of hCG-Induced Gynecomastia
hCG acts virtually identically to luteinizing hormone (LH) and stimulates the Leydig cells of the testes to produce androgens 1. When hCG is administered therapeutically or secreted ectopically by tumors, it increases testosterone production, which is then converted to estradiol through aromatization. This elevated estradiol, combined with the hormonal milieu created by hCG, can trigger breast tissue proliferation 2, 3, 4.
The FDA drug label for hCG specifically warns that "induction of androgen secretion by HCG may induce precocious puberty in patients treated for cryptorchidism" and notes the potential for fluid retention due to androgen effects 1. While the label doesn't explicitly list gynecomastia as an adverse effect in adults, the androgenic stimulation mechanism makes it a recognized clinical consequence.
Clinical Context and Recognition
When hCG Causes Gynecomastia:
Therapeutic use: The 2018 AUA Guideline notes that hCG is used as an alternative therapy in men with testosterone deficiency who wish to maintain fertility, as it promotes endogenous testosterone production 5. During this treatment, the increased testosterone can aromatize to estrogen, potentially causing gynecomastia.
Pathologic hCG secretion: More dramatically, ectopic hCG-secreting tumors (testicular, lung, bladder, mediastinal) commonly present with gynecomastia as the initial symptom 2, 3, 6, 4. These cases typically show:
- Elevated hCG and estradiol
- Elevated total and free testosterone
- Suppressed LH and FSH (due to negative feedback)
- Rapid onset of painful, bilateral breast enlargement
Key Diagnostic Features:
The 2019 EAA Clinical Practice Guidelines recommend that evaluation of adult-onset gynecomastia should include hCG measurement as part of the hormonal workup, specifically to detect hCG-secreting tumors 7. The presence of LH/hCG receptors has been demonstrated in male breast tissue, providing a direct mechanism for hCG's effects 8.
Clinical Pitfalls
Critical warning: In any adult male presenting with rapidly progressing or recent-onset painful gynecomastia, measure serum hCG beta subunit 4. The combination of elevated hCG with suppressed gonadotropins (LH/FSH) and elevated estradiol/testosterone strongly suggests an hCG-secreting tumor requiring urgent investigation 2, 3, 6.
Don't assume therapeutic hCG is safe from this complication: While the AUA guidelines conditionally recommend hCG for fertility preservation in hypogonadal men 5, clinicians should monitor for breast symptoms. The 2018 AUA Guideline specifically states that men who develop gynecomastia or breast symptoms on treatment should undergo monitoring, as symptoms sometimes abate, but estradiol should be measured in those with persistent breast symptoms 5.
Testicular ultrasound is mandatory: Even when hCG is being used therapeutically, if gynecomastia develops, perform testicular ultrasound to exclude a concurrent hCG-secreting testicular tumor, as palpation alone has low sensitivity 7.
Management Approach
For therapeutic hCG-induced gynecomastia: Consider dose reduction or switching to alternative fertility-preserving strategies (selective estrogen receptor modulators or aromatase inhibitors) if breast symptoms are bothersome 5.
For tumor-related cases: Surgical resection of the hCG-secreting tumor typically results in rapid normalization of hCG and estradiol levels, with complete resolution of gynecomastia within 3 months 4, 2.